TAU subjects who had been prescribed medications at baseline that were contraindicated based on the individual subject 's genotype ( i.e. , red bin ) had almost no improvement ( 0.8 % ) in depressive symptoms measured by HAMD-17 at week 10 , which was far less than the 33.1 % improvement ( p = 0.06 ) in the pharmacogenomic guided subjects who started on a red bin medication and the 26.4 % improvement in GeneSight subjects overall ( p = 0.08 ) .